After a recent funding announcement, Isotope Technologies Munich SE (ITM), a radiopharmaceutical biotech company, has opened its new production facility for therapeutic radionuclides in Neufahrn
Beacon Therapeutics Holdings Limited has been launched to develop gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness.
This week, we have a conversation about precision medicine with Tero Silvola, CEO at BC Platforms. We also discuss the acquisition of 4Pharma. The acquisition
Med-Life Discoveries, LP (MLD) is a Canadian biopharmaceutical company dedicated to advancing a therapy to reduce symptoms for a devastating pediatric rare disease, Rhizomelic chondrodysplasia
Owkin, NanoString Technologies and cancer research institutions University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander- Universität Erlangen-Nürnberg, and Charité – Universitätsmedizin Berlin are
Astellas Pharma Inc. has submitted a new drug application (NDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for zolbetuximab. Zolbetuximab is a first-in-class
Quell Therapeutics Ltd, a developer of engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has entered into a collaboration,
Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its antibody-cell conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps
Gene therapy company Kate Therapeutics Inc. (KateTx), has emerged from stealth mode with a $51 million Series A financing. In addition, the company has granted
Spanish-headquartered Minoryx Therapeutics says the U.S. Food and Drug Administration (FDA) has approved its phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat